10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      ESMO-Magnitude of Clinical Benefit Scale (MCBS) group

      other
      1 , 2 ,
      ESMO Open
      BMJ Publishing Group
      Podcast

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Click here to listen to the Podcast Audio Click here to listen Despite all the efforts done so far, access to essential drugs in oncology is still asymmetric. In this podcast, Teresa Amaral, member of the ESMO Young Oncologists Committee, interviews Professor Martine Piccart (Scientific Director of the Institut Jules Bordet, Universite Libre de Bruxelles, Belgium), who shares valuable insights on the work that has been done on this field by the ESMO-MCBS group. The idea behind this working group derived from acknowledging that access to cancer therapies was extremely variable in the European countries. Starting from there, the group developed a scale to assess the magnitude of clinical benefit from new cancer therapies already approved by the European Medicines Agency, allowing recognition of those that ought to be timely available to all European citizens. This scale can be applied in two different settings: the curative and the non-curative settings. Although initially developed to evaluate therapies approved for solid cancers, it has recently been used in haematological malignancies, where it has also been shown to be applicable and performing similarly. The ESMO-MCBS can be used in daily practice by medical doctors and residents to understand the added value of one particular drug, by pharmaceutical companies when designing clinical trials and by patients, aiding them to better understand what to expect from a particular therapy, particularly in terms of quality of life. The ESMO-MCBS has been incorporated in the ESMO guidelines, giving an extra boost to the applicability of this tool, but also increasing the necessity of keeping the evaluations up to date, this being one of the focus of the future activities of this group. You can find more information about the ESMO-MCBS group in publications online (https://doi.org/10.1093/annonc/mdv249 and http://dx.doi.org/10.1136/esmoopen-2017-000216). More information on the ESMO Magnitude of Clinical Benefit Scale: Scale Evaluation Forms V.1.0 and V.1.1 can be found online (https://www.esmo.org/Guidelines/ESMO-MCBS/Scale-Evaluation-Forms-v1.0-v1.1).

          Related collections

          Author and article information

          Journal
          ESMO Open
          ESMO Open
          esmoopen
          esmoopen
          ESMO Open
          BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
          2059-7029
          2019
          8 October 2019
          : 4
          : 5
          : e000594
          Affiliations
          [1 ] departmentCentre for Dermatooncology, Department of Dermatology , Eberhard Karls University , Tuebingen, Germany
          [2 ] Portuguese Air Force Health Care Direction , Lisbon, Portugal
          Author notes
          [Correspondence to ] Dr Teresa Amaral; teresamaral@ 123456gmail.com
          Article
          esmoopen-2019-000594
          10.1136/esmoopen-2019-000594
          6802955
          bf0a6ee5-b16e-474a-91f8-60ac782f120f
          © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

          This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

          History
          Categories
          Podcast
          1506
          Custom metadata
          unlocked

          podcast
          podcast

          Comments

          Comment on this article